Transgenic Group Inc. (TYO:2342)

Japan · Delayed Price · Currency is JPY

210.00

+2.00 (0.96%)

Jun 24, 2026, 3:30 PM JST

18.64% (1Y)

Market Cap	3.46B +30.8%
Revenue (ttm)	13.17B +1.3%
Net Income	-77.00M
EPS	-4.62
Shares Out	16.65M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	75,100
Open	209.00
Previous Close	208.00
Day's Range	208.00 - 216.00
52-Week Range	168.00 - 487.00
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Transgenic Group

Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment and Consulting Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of cl... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Employees 241

Stock Exchange Tokyo Stock Exchange

Ticker Symbol 2342

Full Company Profile

Financial Performance

In fiscal year 2026, Transgenic Group's revenue was 13.17 billion, an increase of 1.30% compared to the previous year's 13.01 billion. Losses were -77.00 million, -92.93% less than in 2025.

Financial Statements